INSULIN RESISTANCE IN POLYCYSTIC OVARY SYNDROME: CLINICAL IMPLICATIONS AND IMPACT ON QUALITY OF LIFE — A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5856Keywords:
Polycystic Ovary Syndrome; Insulin Resistance; Quality Of Life; Hyperandrogenism; Metabolic Risk; Interdisciplinary CareAbstract
Polycystic ovary syndrome (PCOS) is a multifaceted endocrine and metabolic condition affecting women of reproductive age. While historically conceptualized as a reproductive disorder, current evidence indicates that PCOS extends beyond ovulatory dysfunction and hyperandrogenism to include significant metabolic, psychological, and quality of life consequences. Insulin resistance represents a core pathophysiological feature of the syndrome, contributing to hyperinsulinemia, exacerbation of androgen excess, menstrual irregularities, and long term metabolic risk. This narrative review synthesizes current literature on the mechanisms and clinical implications of insulin resistance in PCOS, drawing from peer reviewed studies, systematic reviews, meta analyses, and international guidelines.
Evidence shows that insulin resistance is prevalent across PCOS phenotypes, including in women without obesity, and is strongly associated with impaired glucose metabolism, dyslipidemia, metabolic syndrome, and increased cardiometabolic vulnerability. Psychological burden is also substantial, with many women reporting depressive and anxiety symptoms, body image concerns, fertility related distress, and reduced overall wellbeing. Interactions between metabolic dysfunction, emotional health, and lifestyle factors further contribute to diminished health related quality of life.
Collectively, these findings highlight the need for early metabolic assessment, individualized therapeutic strategies, and interdisciplinary care models addressing both physiological and psychosocial dimensions of PCOS. A comprehensive approach to insulin resistance may improve reproductive, metabolic, and psychological outcomes and support more patient centered long term management.
References
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2(1), 16057. https://doi.org/10.1038/nrdp.2016.57
Barber, T. M., Dimitriadis, G. K., Andreou, A., & Franks, S. (2015). Polycystic ovary syndrome: Insight into pathogenesis and a common association with insulin resistance. Clinical Medicine, 15(6), s72–s76. https://doi.org/10.7861/clinmedicine.15-6-s72
Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary syndrome. Clinical Endocrinology, 95(4), 531–541. https://doi.org/10.1111/cen.14421
Bazarganipour, F., Ziaei, S., Montazeri, A., Foroozanfard, F., Kazemnejad, A., & Faghihzadeh, S. (2014). Health-related quality of life in patients with polycystic ovary syndrome (PCOS): A model-based study of predictive factors. The Journal of Sexual Medicine, 11(4), 1023–1032. https://doi.org/10.1111/jsm.12405
Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016). Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies. Human Reproduction, 31(11), 2619–2631. https://doi.org/10.1093/humrep/dew243
Cooney, L. G., Lee, I., Sammel, M. D., & Dokras, A. (2017). High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Human Reproduction, 32(5), 1075–1091. https://doi.org/10.1093/humrep/dex044
Corbould, A., Kim, Y.-B., Youngren, J. F., Pender, C., Kahn, B. B., Lee, A., & Dunaif, A. (2005). Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. American Journal of Physiology-Endocrinology and Metabolism, 288(5), E1047–E1054. https://doi.org/10.1152/ajpendo.00361.2004
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979). Glucose clamp technique: A method for quantifying insulin secretion and resistance. American Journal of Physiology-Endocrinology and Metabolism, 237(3), E214. https://doi.org/10.1152/ajpendo.1979.237.3.E214
Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 33(6), 981–1030. https://doi.org/10.1210/er.2011-1034
Ehrmann, D. A. (2005). Polycystic ovary syndrome. New England Journal of Medicine, 352(12), 1223–1236. https://doi.org/10.1056/NEJMra041536
Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284. https://doi.org/10.1038/nrendo.2018.24
Garg, D., & Tal, R. (2016). Inositol treatment and ART outcomes in women with PCOS. International Journal of Endocrinology, 2016, 1–9. https://doi.org/10.1155/2016/1979654
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 7(4), 219–231. https://doi.org/10.1038/nrendo.2010.217
Harrison, C. L., Lombard, C. B., Moran, L. J., & Teede, H. J. (2011). Exercise therapy in polycystic ovary syndrome: A systematic review. Human Reproduction Update, 17(2), 171–183. https://doi.org/10.1093/humupd/dmq045
Hollinrake, E., Abreu, A., Maifeld, M., Van Voorhis, B. J., & Dokras, A. (2007). Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertility and Sterility, 87(6), 1369–1376. https://doi.org/10.1016/j.fertnstert.2006.11.039
Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015). Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocrine Research, 40(3), 133–138. https://doi.org/10.3109/07435800.2014.966385
Johnson, N. P. (2014). Metformin use in women with polycystic ovary syndrome. Annals of Translational Medicine, 2(6), 56. https://doi.org/10.3978/j.issn.2305-5839.2014.04.15
Legro, R. S., Kunselman, A. R., Dodson, W. C., & Dunaif, A. (1999). Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. The Journal of Clinical Endocrinology & Metabolism, 84(1), 165–169. https://doi.org/10.1210/jcem.84.1.5393
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012). Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. Human Reproduction Update, 18(6), 618–637. https://doi.org/10.1093/humupd/dms030
Lim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, S., Teede, H. J., & Moran, L. J. (2019). Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Obesity Reviews, 20(2), 339–352. https://doi.org/10.1111/obr.12762
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003). Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ, 327(7421), 951. https://doi.org/10.1136/bmj.327.7421.951
Matsuda, M., & DeFronzo, R. A. (1999). Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care, 22(9), 1462–1470. https://doi.org/10.2337/diacare.22.9.1462
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419. https://doi.org/10.1007/BF00280883
Moghetti, P., & Tosi, F. (2021). Insulin resistance and PCOS: Chicken or egg? Journal of Endocrinological Investigation, 44(2), 233–244. https://doi.org/10.1007/s40618-020-01351-0
Moran, L. J., Hutchison, S. K., Norman, R. J., & Teede, H. J. (2011). Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD007506.pub3
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017). Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews, (2). https://doi.org/10.1002/14651858.CD003053.pub6
Simental-Mendía, L. E., Rodríguez-Morán, M., & Guerrero-Romero, F. (2008). The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metabolic Syndrome and Related Disorders, 6(4), 299–304. https://doi.org/10.1089/met.2008.0034
Spritzer, P. M., Lecke, S. B., Satler, F., & Morsch, D. M. (2015). Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction, 149(5), R219–R227. https://doi.org/10.1530/REP-14-0435
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., Balen, A., Baye, E., Boyle, J., Brennan, L., Broekmans, F., Dabadghao, P., Devoto, L., Dewailly, D., Downes, L., … Yildiz, B. O. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 110(3), 364–379. https://doi.org/10.1016/j.fertnstert.2018.05.004
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
Unfer, V., Carlomagno, G., Rizzo, P., Raffone, E., & Roseff, S. (2011). Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles: A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences, 15(4), 452–457.
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010). Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. The Journal of Clinical Endocrinology & Metabolism, 95(5), 2038–2049. https://doi.org/10.1210/jc.2009-2724
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Martyna Sienicka, Weronika Winiarska, Wiktoria Bełcikowska-Skowron, Aleksandra Siegmund, Marzena Chrapczyńska, Agnieszka Filarecka, Piotr Przybyszewski, Emilia Przybyszewska, Julia Gatniejewska, Paulina Prudzic
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
